Breyanzi: payments to doctors
Payments that named Breyanzi as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1M
- Providers
- 1,153
- Transactions
- 2,269
- Average per transaction
- $447
The per-transaction average — $447 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,153 providers the average total is $879, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | $979,035 | 96.6% |
| Bristol Myers Squibb | $34,377 | 3.4% |